Phaarmasia Ltd
Incorporated in 1981, Phaarmasia Ltd is engaged in manufacturing and marketing of Cosmetics, Oral Contraceptive Pills (OCP) and Combipack with Iron Tablets
- Market Cap ₹ 30.0 Cr.
- Current Price ₹ 43.9
- High / Low ₹ 46.2 / 22.0
- Stock P/E
- Book Value ₹ 15.2
- Dividend Yield 0.00 %
- ROCE -12.0 %
- ROE -11.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 2.88 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.65% over past five years.
- Company has a low return on equity of -6.61% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
34.79 | 13.85 | 15.16 | 12.30 | 13.68 | 14.33 | 18.97 | 23.97 | 19.93 | 16.20 | 16.88 | 27.42 | 28.10 | |
33.75 | 13.19 | 14.32 | 11.35 | 12.94 | 14.19 | 18.31 | 23.24 | 19.11 | 16.26 | 18.62 | 28.97 | 29.46 | |
Operating Profit | 1.04 | 0.66 | 0.84 | 0.95 | 0.74 | 0.14 | 0.66 | 0.73 | 0.82 | -0.06 | -1.74 | -1.55 | -1.36 |
OPM % | 2.99% | 4.77% | 5.54% | 7.72% | 5.41% | 0.98% | 3.48% | 3.05% | 4.11% | -0.37% | -10.31% | -5.65% | -4.84% |
0.01 | 0.01 | 0.00 | 0.07 | 0.01 | 0.58 | 0.53 | 0.60 | 0.58 | 0.89 | 0.47 | 0.52 | 0.61 | |
Interest | 0.30 | 0.02 | 0.02 | 0.03 | 0.01 | 0.01 | 0.04 | 0.04 | 0.04 | 0.01 | 0.00 | 0.04 | 0.07 |
Depreciation | 0.47 | 0.43 | 0.38 | 0.76 | 0.50 | 0.44 | 0.47 | 0.46 | 0.40 | 0.34 | 0.29 | 0.36 | 0.43 |
Profit before tax | 0.28 | 0.22 | 0.44 | 0.23 | 0.24 | 0.27 | 0.68 | 0.83 | 0.96 | 0.48 | -1.56 | -1.43 | -1.25 |
Tax % | 21.43% | 18.18% | 18.18% | 39.13% | 83.33% | 37.04% | 16.18% | 6.02% | 44.79% | 33.33% | 1.28% | 11.89% | |
0.22 | 0.18 | 0.35 | 0.14 | 0.04 | 0.16 | 0.57 | 0.78 | 0.54 | 0.31 | -1.55 | -1.26 | -1.08 | |
EPS in Rs | 0.32 | 0.26 | 0.51 | 0.21 | 0.06 | 0.23 | 0.83 | 1.14 | 0.79 | 0.45 | -2.27 | -1.85 | -1.58 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 8% |
3 Years: | 11% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 18% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 20% |
3 Years: | 13% |
1 Year: | 62% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | -2% |
3 Years: | -7% |
Last Year: | -11% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 |
Reserves | 1.00 | 0.69 | 0.62 | 6.28 | 5.04 | 4.83 | 5.20 | 5.99 | 6.58 | 6.83 | 5.23 | 3.98 | 3.55 |
0.00 | 0.00 | 0.00 | 0.11 | 0.09 | 0.07 | 0.22 | 0.19 | 0.08 | 0.05 | 0.03 | 0.27 | 0.20 | |
15.94 | 17.26 | 5.91 | 6.17 | 6.74 | 7.81 | 9.67 | 20.25 | 20.11 | 8.20 | 9.12 | 17.34 | 17.51 | |
Total Liabilities | 23.77 | 24.78 | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 28.09 |
11.90 | 11.14 | 10.51 | 15.61 | 14.11 | 13.74 | 14.18 | 13.80 | 13.40 | 13.06 | 12.76 | 12.79 | 12.61 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
11.87 | 13.64 | 2.85 | 3.78 | 4.59 | 5.80 | 7.74 | 19.46 | 20.20 | 8.85 | 8.45 | 15.63 | 15.48 | |
Total Assets | 23.77 | 24.78 | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 28.09 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-2.14 | 0.09 | 0.16 | 0.48 | 0.28 | -0.08 | 0.88 | 0.06 | 0.08 | 0.25 | -0.18 | 0.65 | |
0.08 | -0.15 | -0.17 | -0.34 | -0.28 | -0.18 | -0.92 | -0.10 | 0.00 | 0.00 | 0.01 | -0.01 | |
0.02 | 0.00 | 0.00 | 0.12 | 0.16 | -0.02 | 0.08 | 0.04 | -0.11 | -0.02 | 0.00 | -0.16 | |
Net Cash Flow | -2.04 | -0.06 | -0.01 | 0.26 | 0.17 | -0.29 | 0.04 | 0.00 | -0.03 | 0.23 | -0.17 | 0.48 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87.39 | 256.95 | 47.67 | 47.78 | 77.64 | 90.68 | 72.92 | 179.07 | 225.63 | 96.21 | 68.98 | 99.97 |
Inventory Days | 17.03 | 261.72 | 13.98 | 80.49 | 11.77 | 55.86 | 43.40 | 134.51 | 124.67 | 65.84 | 111.66 | 103.36 |
Days Payable | 125.40 | 1,692.02 | 57.90 | 184.68 | 216.27 | 292.87 | 249.28 | 403.08 | 374.43 | 166.48 | 214.10 | 268.79 |
Cash Conversion Cycle | -20.97 | -1,173.34 | 3.74 | -56.42 | -126.86 | -146.33 | -132.96 | -89.49 | -24.13 | -4.43 | -33.46 | -65.47 |
Working Capital Days | -42.91 | -93.82 | -71.75 | -79.23 | -64.04 | -43.05 | -33.67 | -10.35 | 7.33 | 8.11 | -16.87 | -37.27 |
ROCE % | 7.25% | 3.13% | 6.15% | 2.52% | 1.99% | 2.36% | 6.01% | 6.65% | 7.55% | 3.60% | -12.09% | -12.00% |
Documents
Announcements
- Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulation, 2011 For The Year Ended 31St March 2024 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Apr - Certificate under Regulation 74(5) of SEBI (LODR) Reg, 2018 for the Quarter and Financial year ended 31st March 2024.
- Certificate As per Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 3 Apr
- Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations 2015-Reg 3 Apr
- Closure of Trading Window 30 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
Company provides various therapeutic dosage combinations for Ministry of Health & Family Welfare and also for exports. In FY20, company became a Sick Industrial Company under SICA and was referred to BIFR.